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Abstract
Introduction
Chronic hepatitis C (CHC) is a major cause of liver disease worldwide which often leads to
progressive liver inflammation, fibrosis, cirrhosis and hepatocellular carcinoma (HCC). CHC
displays heterogeneous progression depending on a broad set of factors, some of them
intrinsic to each individual such as the patient’s genetic profile. This study aims to evaluate
the contribution of certain genetic variants of crucial interferon alpha and lambda signaling
pathways to the hepatic necroinflammatory activity (NIA) grade of CHC patients.
Methods
NIA was evaluated in 119 CHC patients by METAVIR scale and classified as low (NIA =
0–2, n = 80) or high grade (NIA = 3, n = 39). In a candidate gene approach, 64 SNPs located
in 30 different genes related to interferon pathways (IL-28B, IFNAR1-2, JAK-STAT and
OAS1-3, among others) were genotyped using the Illumina GoldenGate®Genotyping
Assay. Statistical association was determined by logistic regression and expressed as OR
and 95% CI. Those SNPs significantly associated were further adjusted by other covariates.
Results
Seven SNPs located in IL-28B (rs12979860), JAK1 (rs11576173 and rs1497056), TYK2
(rs280519), OAS1 (rs2057778), SOCS1 (rs33932899) and RNASEL (rs3738579) genes were
significantly related to severe NIA grade (p<0.05). Regarding to clinical variables, elevated NIA
was notably associated with aspartate aminotransferase (AST) serum levels >40 IU/L (p<0.05)
but not with other clinical factors. Multivariate logistic regression analysis of these factors
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reflected that AST (>40 IU/L), TYK2 rs280519 (G allele) and RNASEL rs3738579 (G allele)
were factors independently associated with elevated NIA (p<0.05). AST concentration showed
a moderate AUC value (AUC = 0.63), similar to TYK2 (rs280519) and RNASEL (rs3738579)
SNPs (AUC = 0.61, both) in the ROC_AUC analysis. Interestingly, the model including all sig-
nificant variables reached a considerable predictive value (AUC = 0.74).
Conclusion
The identified genetic variants in interferon signaling pathways may constitute useful prog-
nostic markers of CHC progression. Further validation in larger cohorts of patients is
needed.
Introduction
Hepatitis C virus (HCV) is a major cause of liver-related morbidity and mortality, affecting
170 million people worldwide [1]. Natural history of chronic hepatitis C (CHC) is characterized
by a highly variable progression and depending on the extent of liver fibrosis and inflammation
CHC can progress to cirrhosis and hepatocellular carcinoma (HCC) [2]. Although new antiviral
drugs are highly effective in eradicating HCV infection, there is an important percentage of
patients in which the use of these therapies is restricted due to co-morbidities or socio-eco-
nomic reasons [3]. Moreover, recent studies suggest that virus clearance, especially at advanced
stages of disease, does not definitively guarantee healing of liver injury and neither abrogates
the risk of liver decompensation or HCC development [4–6]. Therefore, the identification of
non-invasive biomarkers that accurately predict the evolution of the disease might notably
improve the prevention and clinical management of these patients, especially in the view of
unexpected elevated frequency of hepatic and extrahepatic events related to current interferon
(IFN)-free therapy. The immune system plays a central role in the therapeutic response and in
the appearance of various disorders associated with CHC [7,8], and several genome-wide asso-
ciation studies have revealed the strong association of IL-28B rs12979860 polymorphism with
the attainment of sustained virological response (SVR) in patients treated with the conventional
antiviral therapy (pegylated-interferon and ribavirin) [9–11]. Similarly, other SNPs located in
interferon stimulated genes (ISGs) were also independently related to SVR improving the pre-
dictive value of IL-28B (rs12979860) for combination treatment outcome [12].
On the other hand, the implication of inflammation in the progression of CHC and devel-
opment of HCC is well established and several inflammatory signaling pathways link inflam-
mation and cancer [13,14]. Therefore, the progression of CHC could be influenced by host
genetic variants of innate immunity response genes. Indeed, an important association between
the IL-28B C/C rs12979860 genotype and higher degree of hepatic inflammation and fibrosis
in CHC patients has been described [15–17]. Based on these results, the present study aims to
evaluate the contribution of different genetic variants, located in the crucial interferon alpha
and lambda signaling pathways, on the hepatic necroinflammatory activity of CHC patients.
Materials and methods
Patients and study design
The study population included 119 patients of European descent from Hospital Universitario
de La Princesa, Hospital Universitario San Cecilio de Granada and Hospital Universitario
Genetic markers of liver inflammation in CHC
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Central de Asturias. All patients gave their written informed consent to participate in the
genetic analysis before their enrollment. This retrospective cohort study was approved by the
local Ethics Committee of Hospital de La Princesa (Madrid, Spain) and good clinical practice
guidelines were followed.
Included patients had previous diagnosis of HCV infection, which was confirmed by the
presence of detectable HCV RNA in serum. HCV RNA levels and HCV genotype were deter-
mined using the COBAS AMPLICOR1 assay (Roche Molecular Diagnosis GmbH, Mannheim,
Germany) and the reverse-hybridization line probe assay (INNO-LiPAHCV; Innogenetics,
Zwijndreht, Belgium), respectively. At Hospital Universitario San Cecilio, viral load was deter-
mined the by HCV Ampliprep TaqMan, Roche Molecular System (cutoff<15 IU/mL). Patients
showed no evidence of HBV infection, HIV infection, alcoholism, autoimmune, or drug-
induced liver disease. Patients’ serum samples were also subjected to routine laboratory tests in
the biochemical laboratory of each center using common commercial methods, measuring ala-
nine transaminase (ALT), aspartate aminotransferase (AST) and gamma glutamyl transferase
(GGT).
Necroinflammatory activity assessment
Liver biopsies, obtained for diagnostic purposes, were analyzed histologically according to the
METAVIR classification system [18], which scores NIA from 0 to 3: A0, no histologic necroin-
flammatory activity; A1, minimal activity; A2, moderate activity and A3, severe activity.
SNP selection and genotyping
DNA was isolated from whole blood samples from Hospital Universitario de La Princesa and
Hospital Universitario San Cecilio by using a MagNA Pure DNA isolation kit (Roche Diagnos-
tics, Mannheim, Germany) in accordance with the manufacturer’s instructions and stored at
−80˚C until assay. Genomic DNA was extracted from peripheral blood samples from Hospital
Universitario Central de Asturias with the Magtration-MagaZorb DNA Common Kit-200 N
using the Magtration 12GC system (Precision System Science Co., Ltd., Woerrstadt, Germany)
and the Maxwell 16 Blood Purification Kit using the Maxwell 16 Instrument (Promega Corpo-
ration, Madison, Wisconsin, USA).
A total of 63 SNPs located in 30 interferon signaling pathway and interferon stimulated
genes were selected by their tagSNP condition (tagSNPs capture most of the genetic variation
in a region) or location in key regulatory regions as described in the HapMap project, Release
no. 27, Phase II and III (www.hapmap.org) for the CEU population. The specific location of
each SNP (coding/non-coding region and chromosomal position) is detailed in (S1 Table).
SNPs with an estimated minor allele frequency of<5%, an estimated r2<0.8 between two
SNPs in the same gene or with low predicted quality for being genotyped were discarded. Such
strategy allows to capture 341 SNPs (r2>0.8; S1 Table) from genotyping 63 variants (Golden-
Gate Genotyping Assay, Illumina Inc., San Diego, CA, USA) at CICbioGUNE (Center for
Cooperative Research in Biosciences, Vizcaya, Spain). Complementarily, the IL-28B
rs12979860 was genotyped by polymerase chain reaction, as described [19].
Statistical analysis
Hardy–Weinberg equilibrium and allele/genotype frequencies were calculated using SNPStats
software [20]. The association between SNPs and NIA grade and the most accurate model of
inheritance were determined by logistic regression analysis and expressed as odds ratio, 95%
confidence interval and p value.
Genetic markers of liver inflammation in CHC
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Clinical variables were expressed as medians and 1st-3rd quantiles or number of patients
and percentages, except for age (median and range). Associations between variables and NIA
were assessed by Mann-Whitney U-test or Chi-squared test. Two-tailed p values below 0.05
were considered significant (SPSS version 15.0; SPSS Inc., Chicago, IL, USA).
Subsequently, significant clinical variables and SNPs were analyzed by multivariate logistic
regression using a step-backward method, in which none of the variables was forced to be
included into the model. ROC analyses were performed to discriminate the power of factors
independently associated with inflammatory grade (SPSS version 15.0; SPSS Inc., Chicago, IL,
USA).
Results
Clinical characteristics related to necroinflammatory activity grade
Main clinical characteristics of the 119 patients included in the study are summarized in
Table 1. Patients were predominantly men (64%), infected by viral genotype 1 (88%) and with
a median age of 45 years at the time of the liver biopsy. According to METAVIR score, 67% of
patients presented a moderate grade of necroinflammatory activity (NIA2). Patients with
severe inflammation score (NIA = 3) showed lower viral load and higher serum levels of AST
compared to patients with moderate NIA grade (Table 1). No significant differences were
found concerning to the other clinical characteristics.
Genetic variants associated with necroinflammatory activity
Genotype frequencies of each SNP and its association with necroinflammatory activity are
detailed in (S2 Table). Of the 64 interferon-related SNPs, five were excluded of the statistical
analysis, three monomorphic SNPs (rs11575221, rs11575216 and rs7977692) and two SNPs
(rs1061502 and rs17860115), on the basis of their call rate (<80%). SNPs included in the asso-
ciation analysis (n = 59) followed the Hardy–Weinberg equilibrium.
Seven SNPs located in IL-28B (rs12979860), JAK1 (rs11576173 and rs1497056), OAS1
(rs2057778), RNASEL (rs3738579), TYK2 (rs280519) and SOCS1 (rs33932899) genes were sig-
nificantly related to severe NIA grade (Table 2, p<0.05). Interestingly, IL-28B T allele, associ-
ated previously with poor response to interferon-based therapy, was related to lower NIA
score in our group of patients (p = 0.031). In fact, IL-28B C/C genotype was more frequent in
Table 1. Clinical characteristic of the patients included in this study.
Overall (n = 119) NIA2 (n = 80) NIA = 3 (n = 39) p value
Sex (W/M) 36% / 64% 34% / 66% 41% / 59% ns
VG (1/non1) 88% / 12% 88% / 12% 90% / 10% ns
Age (years old) 45 (21–67) 46 (21–67) 45 (25–67) ns
VLx10-5 (IU/mL) 11 (5–23) 12 (5–30) 7 (5–13) 0.01
ALT (IU/L) 72 (51–115) 69 (48–102) 82 (60–146) ns
AST (IU/L) 47 (36–65) 43 (33–58) 58 (41–75) 0.005
GGT (IU/L) 45 (28–83) 41 (27–91) 50 (29–81) ns
Fibrosis1 (FIB2/FIB = 3–4) 73% / 27% 77% / 23% 64% / 36% ns
Data are shown as median and 1st-3rd quantiles except for age (median and range) and sex, viral genotype and fibrosis (percentage of patients).
1Only 104 data available.
NIA, necroinflammatory activity; VG, Viral Genotype; VL, Viral Load; W, women; M, men; IU, international units; ALT, alanine transaminase; AST, aspartate
aminotransferase; GGT, gamma glutamyl transferase; FIB, fibrosis stage; ns, non significant.
https://doi.org/10.1371/journal.pone.0180927.t001
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patients with severe NIA grade (38%) than in patients presenting moderate liver inflammation
(25%). JAK1 rs14907056 G allele showed a higher frequency among patients with severe NIA
grade (21% vs. 10% in moderate NIA). Additionally, JAK1 rs11576173 A/A genotype showed
to be more frequent among patients with severe NIA, although this result could be doubtful
because of the total number of patients carrying this genotype (n = 5). Similarly, rs2057778
C/C and rs33932899 G/G genotypes located in OAS1 and SOCS1, respectively, showed a
slight relation to severe NIA grade; however, only 5 and 3 patients carried the risk genotypes
(Table 2). One of the SNPs analyzed in RNASEL (rs3738579), an interferon stimulated gene
(ISG), displayed an association with liver inflammation, being the G allele related to severe
NIA (p = 0.036). TYK2 rs280519 showed the stronger association with NIA grade: while the A/
A genotype was present in near 30% of the patients with moderate NIA, only 8% of the patients
with severe liver inflammation carried this genotype (p = 0.009).
Multivariate logistic regression and ROC-AUC analyses
Main clinical characteristics and the seven SNPs found in association with NIA grade were
included in a multivariate logistic regression analysis (Table 3). Regarding to clinical variables,
elevated NIA was notably associated with AST serum levels>40 IU/L (p = 0.01), but not with
other clinical factors (such as viral genotype, ALT, GGT or viral load). In addition, TYK2
rs280519 and RNASEL rs3738579 were independent factors strongly associated with elevated
NIA (p = 0.02, both).
It must be noted that neither TYK2 rs280519 nor RNASEL rs3738579 SNPs were signifi-
cantly related to other clinical variables such as viral load, AST, ALT, GGT or fibrosis stage (S3
Table).
ROC_AUC analysis of each variable associated with NIA in the multivariate analysis was
performed to assess their putative predictive value (Fig 1). AST serum level had the highest
AUC value (AUC = 0.63) followed by TYK2 rs280519 and RNASEL rs3738579 (AUC = 0.61,
both). Nonetheless, the model including all the above variables showed the best predictive
value (AUC = 0.74).
Table 2. Genetic variants associated with severe necroinflammatory activity in chronic hepatitis C patients.
Locus SNP Model Genotype NIA2 NIA = 3 p value
IL-28B rs12979860 Additive C/C 20 (25.3%) 15 (38.5%) 0.031
C/T-T/T 59 (74.7%) 24 (61.5%)
JAK1 rs11576173 Recessive G/G-A/G 70 (98.6%) 34 (89.5%) 0.034
A/A 1 (1.4%) 4 (10.5%)
rs1497056 Dominant A/A 60 (81.1%) 21 (60%) 0.021
A/G-G/G 14 (18.9%) 14 (40%)
OAS1 rs2057778 Recessive A/A-A/C 74 (97.4%) 34 (87.2%) 0.036
C/C 2 (2.6%) 5 (12.8%)
SOCS1 rs33932899 Recessive C/C-G/C 75 (100%) 34 (91.9%) 0.034
G/G 0 (0%) 3 (8.1%)
RNASEL rs3738579 Dominant A/A 33 (43.4%) 9 (23.7%) 0.036
A/G-G/G 43 (56.6%) 29 (76.3%)
TYK2 rs280519 Recessive G/G-A/G 50 (71.4%) 34 (91.9%) 0.009
A/A 20 (28.6%) 3 (8.1%)
IL-28B, interferon lambda 3; JAK1, Janus kinase 1; OAS1, 2’-5’-oligoadenylate synthetase 1; RNASEL, ribonuclease L; TYK2, Tyrosine kinase 2; SOCS1,
Suppressor of cytokine signaling 1. Call rate of each SNP90% (n107).
https://doi.org/10.1371/journal.pone.0180927.t002
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Discussion
As known, HCV clearance, CHC progression and response to treatment is driven by multiple
and complex interactions among host, viral and environmental factors [21]. Innate immunity
constitutes the first line of defense against HCV infection and triggers the synthesis of interfer-
ons (IFNs), chief antiviral factors able to reprogram cellular status by the induction of multiple
genes (IFN-stimulated genes, ISGs) which limit virus replication and the subsequent liver
damage [22–24]. Therefore, host genetic polymorphisms in genes involved in IFN signaling
may notably influence the onset and progression of the disease as has been demonstrated for
IL-28B [9–11].
Table 3. Clinical and genetic factors associated with NIA grade in the univariate and multivariate logistic regression analyses.
Factor Univariate Multivariate
OR CI 95% p p
Sex W 1 - -
M 0.73 0.33–1.62 ns
Viral Genotype 1 1 - -
non1 0.8 0.20–2.50 ns
Age (years old) 40 1 - -
>40 0.63 0.28–1.41 ns
Fibrosis stage FIB2 1
FIB = 3–4 1.96 0.79–4.89 ns -
Viral Load (IU/mL) 6105 1 - -
>6105 0.76 0.34–1.74 ns
ALT (IU/L) 40 1 - -
>40 0.76 0.23–2.70 ns
AST (IU/L) 40 1 - 0.01
>40 2.43 1.07–5.86 0.0003
GGT (IU/L) 30 1 - -
>30 1.35 0.58–3.31 ns
IL-28B C/C 1 - ns
rs12979860 C/T-T/T 0.51 0.27–0.96 0.031
JAK1 A/A 1 - ns
rs1497056 A/G-G/G 2.86 1.17–6.97 0.021
JAK1 G/G-A/G 1 - ns
rs11576173 A/A 8.24 0.89–76.53 0.034
OAS1 A/A-A/C 1 - ns
rs2057778 C/C 5.44 1.01–29.47 0.036
RNASEL A/A 1 - 0.02
rs3738579 A/G-G/G 2.47 1.03–5.93 0.036
TYK2 G/G-A/G 1 - 0.02
rs280519 A/A 0.22 0.06–0.80 0.009
SOCS1 C/C-G/C 1.00 ns
rs33932899a G/G NA NA 0.034
aOR cannot be calculated as the value of one genotypic group is 0.
OR, odds ratio; CI, Confidence interval; W, women; M, men; IU, international units; ALT, alanine transaminase; AST, aspartate aminotransferase; GGT,
gamma glutamyl transferase; FIB, fibrosis stage; IL-28B, interferon lambda 3; JAK1, Janus kinase 1; OAS1, 2’-5’-oligoadenylate synthetase 1; RNASEL,
ribonuclease L; TYK2, Tyrosine kinase 2; SOCS1, Suppressor of cytokine signaling 1; ns, non significant; NA, Not Applicable.
https://doi.org/10.1371/journal.pone.0180927.t003
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Interestingly, in this study we have inspected multiple SNPs located at numerous IFN
related genes finding an independent association of some of them with the NIA of CHC
patients. In particular, rs280519 and rs3738579 showed a significant influence in the grade of
the disease and displayed a considerable individual predictive performance, which was sub-
stantially improved when they were simultaneously considered in addition to AST serum lev-
els (AUC-ROC = 0.74).
The upregulation of many ISGs has been associated with decreased HCV viral RNA levels
in the liver of CHC patients as well as in infected hepatocytes [25]. Among them, the OAS/
RNaseL pathway constitutes a key antiviral mechanism triggered by IFNs [26]. 2–5OAS pro-
teins are stimulated by IFNs to synthesize 2-5A oligoadenylates that activate RNaseL to cleave
dsRNA [27,28]; amazingly, the response of CHC patients to IFN-based treatment is related to
RNaseL and it has been described that NS5a can inhibit IFN signaling through its direct bind-
ing to 2–5OAS [29]. Hence, the strength of this interaction may depend on different viral
strains and it has been suggested as the basis through which IFN-resistant viral genotype 1
evade nucleolytic cleavage [30]. Similarly, the efficiency of OAS/RNaseL pathway might result
notably altered by the herein identified genetic variants and could be determinant for the pro-
gression of the liver disease. In the present study, we found the G allele of the rs3738579 associ-
ated with a higher liver inflammation grade. This SNP located at the 5’ UTR region is in
linkage disequilibrium (r2>0.8) with other ten SNPs in European descent population (data
from the 1000 Genomes Project Phase 3, CEU population [31]). Interestingly, one of them,
rs486907, causes an amino acid change (R/Q) at position 462 of RNaseL (S4 Table) which pro-
duces a lower RNaseL activity leading to increased cancer risk [32]. This possible effect could
explain the higher liver inflammation found in CHC patients carrying the risk allele due to
lower efficiency of HCV cleavage. However, further functional studies are needed to confirm
Fig 1. ROC curve analyses of independently associated factors with necroinflammatory activity in
chronic hepatitis C patients. AUC of the variables associated with NIA grade: AST serum levels >40IU/mL
(AUC = 0.63), risk allele of RNASEL rs3738579 and TYK2 rs280519 (AUC = 0.61, both); and the multivariate
regression model including all the above variables (AUC = 0.74).
https://doi.org/10.1371/journal.pone.0180927.g001
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these results. The other SNPs in linkage disequilibrium with rs3738579, located upstream and
downstream RNaseL, have not been related to functional or transcriptional changes to date (S4
Table).
Tyk2 signaling is shared by both type I and III IFNs and its altered expression as well as
some Tyk2 genetic variants have been implicated in the pathogenesis of numerous autoim-
mune diseases such as rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis,
diabetes, ulcerative colitis and Crohn’s disease [33]. Furthermore, lower Tyk2 expression levels
were observed in HCV subgenomic replicon cell-lines unable to respond to IFNλ [34]. On
the other hand, HCV Core reduced the phosphorylation levels of Tyk2 and Jak1, limiting the
response to IFN-α [35]. Interestingly, rs280519 G allele was related to severe NIA grade in
CHC patients in this study. Although this SNP does not cause an amino acid variant, its loca-
tion in the splice site of the intronic region of TYK2makes this SNP of particular interest for
transcriptional regulation. Four SNPs were found in linkage disequilibrium with rs280519 in
the last data released by The 1000 Genomes Project (Phase 3 [31]), all of them located at intron
regions except for rs280497 whose G allele seems to affect a transcriptional binding site at pro-
moter flaking region (data from Ensembl [36,37]). In addition, TYK2 is located at Chromo-
some 19 and surrounded by genes involved in key immune processes such as ICAM (S1 Fig
from SNAP [38]). Those findings highlight the importance of developing an in depth func-
tional study focused on elucidating the prognostic potential of rs280519 or the linked SNPs for
the progression of CHC and other inflammatory pathologies.
Further validation of the above described genetic signature may entail a great interest for
accurate prediction of CHC patients with higher risk of CHC progression, with special atten-
tion to the unexpected elevated occurrence/recurrence of hepatic and extrahepatic manifesta-
tions related to current IFN-free based therapies.
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